Trial Profile

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery restenosis; Myocardial infarction; Stroke
Focus Therapeutic Use
Acronyms EXCEL
Sponsors Abbott Laboratories

Most Recent Events

22 Dec 2020 Results published in the American Journal of Cardiology
06 Oct 2020 Results published in the Journal of the American College of Cardiology
22 Apr 2020 Results assessing the association between smoking status and clinical outcomes among patients undergoing left main coronary artery (LM) revascularization by contemporary PCI or coronary artery bypass grafting (CABG) published in the American Journal of Cardiology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com